
CLAIMS

1. A compound of formula (I):



(I) ,





or a pharmaceutically acceptable salt or solvate thereof;





wherein:





X, Y, and Z are each independently N or CR^{1b}, provided that at least one and no more than two of X, Y, and Z are N;

L is selected from a direct bond, $-NR^4C(=O)-$, and $-C(=O)NR^4-$;

R^1 is selected from methoxy, $-R^5N(R^6)_2$, alkenyl,

, , , ,

, , , ,

, , , and ;

each ---- is independently a single or double bond such that all valences are satisfied;

each R^{1a} is independently alkyl, halo, haloalkyl, $-R^5OR^6$, $-R^5N(R^6)_2$, $-R^5OC(=O)R^6$, optionally substituted cycloalkyl, or $-R^5C(=O)OR^6$;

A is O, N, or C;

each R^{1b} is independently hydrogen, halo, alkyl, or haloalkyl;

R^{2a} and R^{2b}, together with the carbon to which they are attached, form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heterocyclyl, or an optionally

substituted heteroaryl;

or R^{2a} is hydrogen or alkyl and R^{2b} is an optionally substituted heterocyclyl or an optionally substituted cycloalkyl;

or R^{2a} and R^{2b} are both alkyl;

or R^{2a} is alkyl and R^{2b} is haloalkoxy;

R^3 is selected from alkyl, cyanoalkyl, $-R^5OR^6$, $-R^5N(R^6)_2$, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heterocyclyl, an optionally substituted heteroaryl, an optionally substituted cycloalkylalkyl, and an optionally substituted heterocyclylalkyl;

R^4 is hydrogen or alkyl;






each R^5 is independently a direct bond or an optionally substituted alkylene chain;

each R^6 is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, or optionally substituted arylalkyl;

or two R^6's, together with the nitrogen to which they are both attached, form an optionally substituted heterocyclyl; and

n is 0, 1, 2, 3, 4, or 5.

2. The compound of Claim 1, wherein the compound has the formula selected from:



(Ia),

(Ib),

(Ic),

(Id), and

(Ie);

and R^1, R^{1b}, R^{2a}, R^{2b}, L and R^3 are as defined in Claim 1,

or a pharmaceutically acceptable salt, or solvate thereof.

3. The compound of any one of Claims 1-2, wherein:

R^1 has one of the following structures:




wherein:


n is 1, 2, 3, 4, or 5;

or a pharmaceutically acceptable salt, or solvate thereof.

4. The compound of any one of Claims 1-3, wherein:

R^1 has one of the following structures:





or a pharmaceutically acceptable salt, or solvate thereof.

5. The compound of any one of Claims 1-4, wherein:

R^{2a} and R^{2b}, together with the carbon to which they are attached, form an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, or an optionally substituted heteroaryl;

or a pharmaceutically acceptable salt, or solvate thereof.

6. The compound of any one of Claims 1-4, wherein:

R^{2a} and R^{2b}, together with the carbon to which they are attached, form an optionally substituted heterocyclyl;

or a pharmaceutically acceptable salt, or solvate thereof.

7. The compound of any one of Claims 1-4, wherein:

R^{2a} is hydrogen or alkyl and R^{2b} is an optionally substituted heterocyclyl or an optionally substituted cycloalkyl; or


R^{2a} and R^{2b} are both alkyl; or


R^{2a} is alkyl and R^{2b} is haloalkoxy;


or a pharmaceutically acceptable salt, or solvate thereof.

8. The compound of any one of Claims 1-4, wherein:

R^{2a} and R^{2b}, together with the carbon to which they are attached, form one of the following structures:





,


,

R^{7a} is hydrogen, alkyl, haloalkyl, $-R^{7c}C(=O)R^{7d}$, $-R^{7c}C(=O)OR^{7d}$, or heterocyclyl;

each R^{7b} is independently alkyl, halo, haloalkyl, cyano, $–R^{7c}OR^{7d}$, or $–R^{7c}OC(=O)R^{7d}$, or two R^{7b}'s, together with the carbon to which they are both attached join to form –C(=O)-;

each R^{7c} is independently a direct bond or an optionally substituted alkylene chain;

each R^{7d} is independently hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, or optionally substituted arylalkyl;

or two R^{7d}'s, together with the nitrogen to which they are both attached, form an optionally substituted heterocyclyl; and

m is 0, 1, 2, 3, 4, or 5,

or a pharmaceutically acceptable salt, or solvate thereof.

9. The compound of any one of Claims 1-8, wherein:

R^3 is selected from alkyl, cyanoalkyl, $-R^5OR^6$, and $R^5N(R^6)_2$;

or a pharmaceutically acceptable salt, or solvate thereof.

10. The compound of any one of Claims 1-8, wherein:

R^3 is selected from an optionally substituted cycloalkyl and an optionally substituted aryl;

or a pharmaceutically acceptable salt, or solvate thereof.

11. The compound of any one of Claims 1-8, wherein:

R^3 is an optionally substituted heterocyclyl;

or a pharmaceutically acceptable salt, or solvate thereof.

12. The compound of any one of Claims 1-8, wherein:

R^3 is an optionally substituted heteroaryl;

or a pharmaceutically acceptable salt, or solvate thereof.

13. The compound of any one of Claims 1-8, wherein:


R^3 is selected from an optionally substituted cycloalkylalkyl and an optionally


substituted heterocyclylalkyl;

or a pharmaceutically acceptable salt, or solvate thereof.

14. The compound of any one of Claims 1-8, wherein:

R^3 has one of the following structures:





wherein:

R^{8a} is hydrogen, alkyl, haloalkyl, -C(=O)OR^{8d}, optionally substituted aryl, optionally substituted heterocyclylalkyl, optionally substituted cycloalkylalkyl, or optionally substituted cycloalkyl;

each R^{8b} is independently alkyl, optionally substituted cycloalkyl, cyano, halo, -$R^{8c}OR^{8d}$, –$OR^{8c}N(R^{8d})_2$, –C(=O)$N(R^{8d})_2$, –$R^{8c}N(R^{8d})_2$, or optionally substituted heterocyclyl,

each R^{8c} is independently a direct bond or an optionally substituted alkylene chain;

each R^{8d} is independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted cycloalkyl, or optionally substituted cycloalkylalkyl;

or two R^{8d}'s, together with the nitrogen to which they are both attached, form an optionally substituted heterocyclyl;

p is 0, 1, 2, 3, 4, or 5;

or a pharmaceutically acceptable salt, or solvate thereof.

15. The compound of any one of Claims 1-14, wherein:

L is selected from a direct bond, -C(=O)NR^4-, -NR^4C(=O)-, and -NR^4C(=O)-;













or a pharmaceutically acceptable salt, or solvate thereof.













16. The compound of any one of Claims 1-15, wherein:













R^4 is selected from hydrogen and methyl;


or a pharmaceutically acceptable salt, or solvate thereof.

17. The compound of any one of claims 1-3 selected from














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,













,













,













,














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,














N
N
F
F
O
HN
N
H
HCl
F
N
,

N
N
F
HN
O
F
F
O
F
F
N
N
,

N
O
F
O
NH
F
F
F
N
,

N
N
O
HN
F
N
F
N
,

H3C
O
N
S
F
HN
O
F
F
O
F
N
N
,

Br
N
O
F
O
NH
F
F
F
N
,

N
N
O
F
F
HN
N
F
N
,

F
F
N
N
F
HN
O
F
F
O
F
N
N
,

N
O
F
O
NH
F
F
F
N
,

O
HN
N
O
N
,

H3C
O
N
O
F
HN
O
F
F
O
F
N
N
,

H3C
N
O
F
O
NH
F
F
F
N
,














,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,













,













,













,













,













,














,

,

,

,

,

,

,

,

,

,

,

,











,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

P1,D1
,

,

,

P2,D1
,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,













,














,

,

,

,

,

,

,

,

,

,

,

,













,













,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,













,














,

,

,

,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,













,

,


,

,

,

,

,

,

,

,

,

,

,

,













,













,


,

,

,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,













,

,

,


,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,













,













,

,


,

,

,

,

,

,

,

,

,

,

,



,

,

,

,

,

,

,

,

,

,

,

,














,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,













,













,













,












,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

, or

;

or a stereoisomer, enantiomer, tautomer or mixture thereof; or a pharmaceutically acceptable salt, or solvate of said compound, stereoisomer, enantiomer, tautomer, or mixture thereof.

18. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of any one of claims 1-17 or a pharmaceutically acceptable salt, or solvate thereof.

19. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of a disease or condition in a mammal modulated by a voltage-gated sodium channel.

20. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of a disease or condition in a mammal, wherein the disease or condition is selected from epilepsy, seizure disorders, partial seizures, generalized seizures, photosensitive epilepsy, self-induced syncope, intractable epilepsy, Angelman syndrome, benign rolandic epilepsy, CDKL5 disorder, childhood and juvenile absence epilepsy, Dravet syndrome, frontal lobe epilepsy, Glut1 deficiency syndrome, hypothalamic hamartoma, infantile spasms/West's syndrome, juvenile myoclonic epilepsy, Landau-Kleffner syndrome, Lennox-Gastaut syndrome (LGS), epilepsy with myoclonic-absences, Ohtahara syndrome, Panayiotopoulos syndrome, PCDH19 epilepsy, progressive myoclonic epilepsies, Rasmussen's syndrome, ring chromosome 20 syndrome, reflex epilepsies, temporal lobe epilepsy, Lafora progressive myoclonus epilepsy, neurocutaneous syndromes, tuberous sclerosis complex, early infantile epileptic encephalopathy, early onset epileptic encephalopathy, generalized epilepsy with febrile seizures plus (GEFS+), Rett syndrome, multiple sclerosis, Schizophrenia, autism, ataxia, hypotonia and paroxysmal dyskinesia, Alzheimer's disease, Tauopathies, Pick's disease, progressive supranuclear palsy, corticobasal syndrome, frontotemporal dementias, Argyrophilic grain disease, frontotemporal lobar degeneration, globular glial tauopathies, MAPT mutation, primary age-related tauopathy, neurofibrillary tangle dementia, chronic traumatic encephalopathy (CTE), aging-related tau astrogliopathy, Richardson syndrome, Down Syndrome, parkinsonism, pure akinesia with gait freezing, motor neuron symptoms or cerebellar ataxia, posttraumatic stress disorders (PTSD), and any combination thereof.